Biogen Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a two-day winning streak.
BioXcel Therapeutics Provides Clinical and Business Update
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...
Piper Sandler Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Biogen Inc. stock underperforms Monday when compared to competitors
Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...